ADC Therapeutics SA (ADCT) income statement
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.37+0.02 (+1.48%)
Close on Nov 18, 2026Market cap $174.91MP/E –Yield –
ADC Therapeutics SA income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 89.0%
- Operating margin
- -97.7%
- Net margin
- -95.7%
- Return on equity, FY2025
- 73.4%
Financial strength
- Current ratio
- 3.05
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 242.2%
Valuation
- P/E ratio
- –
- Price to sales
- 2.06
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?